DK2650003T3 - Nedbrydelige clostridiumtoksiner - Google Patents

Nedbrydelige clostridiumtoksiner Download PDF

Info

Publication number: DK2650003T3
Authority: DK; Denmark
Prior art keywords: degradable; clostridium toxins; clostridium; toxins; degradable clostridium
Prior art date: 2010-05-20

Application number

DK13176290.8T

Other languages

English (en)

Inventor

Lance E Steward

Ester Fernandez-Salas

Marcella A Gilmore

Joseph Francis

Kei Roger Aoki

Sanjiv Ghanshani

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-20

Filing date

2011-05-19

Publication date

2016-11-28

2011-05-19 Application filed by Allergan Inc filed Critical Allergan Inc

2016-11-28 Application granted granted Critical

2016-11-28 Publication of DK2650003T3 publication Critical patent/DK2650003T3/da

Links

241000193403 Clostridium Species 0.000 title 1
239000003053 toxin Substances 0.000 title 1
231100000765 toxin Toxicity 0.000 title 1
108700012359 toxins Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)

DK13176290.8T 2010-05-20 2011-05-19 Nedbrydelige clostridiumtoksiner DK2650003T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34657810P	2010-05-20	2010-05-20
EP11724483.0A EP2571509B1 (en)	2010-05-20	2011-05-19	Degradable clostridial toxins

Publications (1)

Publication Number	Publication Date
DK2650003T3 true DK2650003T3 (da)	2016-11-28

Family

ID=44484018

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK16181227.6T DK3106170T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner
DK11724483.0T DK2571509T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner
DK13176290.8T DK2650003T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK16181227.6T DK3106170T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner
DK11724483.0T DK2571509T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner

Country Status (20)

Country	Link
US (13)	US8512992B2 (da)
EP (3)	EP2650003B1 (da)
JP (4)	JP6148979B2 (da)
KR (4)	KR102321664B1 (da)
CN (1)	CN103228286B (da)
AR (1)	AR081407A1 (da)
AU (1)	AU2011255525B2 (da)
BR (1)	BR112012029666A2 (da)
CA (1)	CA2799969C (da)
DK (3)	DK3106170T3 (da)
ES (3)	ES2596128T3 (da)
IL (1)	IL223100B (da)
MX (2)	MX369263B (da)
NZ (2)	NZ703378A (da)
RU (1)	RU2561465C2 (da)
SG (2)	SG185663A1 (da)
TW (1)	TWI516594B (da)
UA (1)	UA108646C2 (da)
WO (1)	WO2011146704A1 (da)
ZA (1)	ZA201208753B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2750371B2 (ja)	1989-05-12	1998-05-13	触媒化成工業株式会社	接触分解用触媒組成物およびそれを使用した重質炭化水素油の接触分解方法
MX369263B (es) *	2010-05-20	2019-11-04	Allergan Inc	Toxinas de clostridium degradables.
JP6148676B2 (ja) *	2011-11-04	2017-06-14	リポテック，エセ．ア．	活性化受容体を阻害するペプチド、および化粧品組成物または薬学的組成物におけるそれらの使用
EP2798077A2 (en)	2011-12-31	2014-11-05	Allergan, Inc.	Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
EP2804623B1 (en)	2012-01-12	2019-08-07	Bioverativ Therapeutics Inc.	Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en)	2012-02-15	2019-02-06	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
LT3564260T (lt)	2012-02-15	2023-01-10	Bioverativ Therapeutics Inc.	Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2861732B1 (en) *	2012-05-30	2019-06-19	The University of Utah Research Foundation	Matrix metalloproteinase cleavable protein polymers for cancer gene therapy
CN110054699A (zh)	2012-07-11	2019-07-26	比奥贝拉蒂治疗公司	具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US20140170132A1 (en)	2012-12-18	2014-06-19	Allergan, Inc.	Prophylatic treatment of herpes recurrence
CN104212833A (zh) *	2013-05-30	2014-12-17	江苏大学	一种新型转基因质粒载体及其构建方法、体内含新型重组基因家蚕的培育方法
EP3013359A4 (en) *	2013-06-28	2017-01-25	Biogen MA Inc.	Thrombin cleavable linker
GB201312317D0 (en)	2013-07-09	2013-08-21	Syntaxin Ltd	Cationic neurotoxins
TWI667255B (zh)	2013-08-14	2019-08-01	美商生物化學醫療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
KR102488220B1 (ko)	2013-09-25	2023-01-12	싸이톰스 테라퓨틱스, 인크.	매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
US9216210B2 (en) *	2013-12-23	2015-12-22	Dublin City University	Multiprotease therapeutics for chronic pain
SG11201605242YA (en)	2014-01-10	2016-07-28	Biogen Ma Inc	Factor viii chimeric proteins and uses thereof
KR102466591B1 (ko) *	2014-01-31	2022-11-14	싸이톰스 테라퓨틱스, 인크.	마트립타제 및 ｕ-플라스미노겐 활성화인자 기질 및 다른 절단성 모이어티 및 이의 사용 방법
CA2947006A1 (en)	2014-04-30	2015-11-05	Eric A. Forssen	Formulations of biologics for intravesical instillation
KR20220048046A (ko)	2014-07-31	2022-04-19	알러간, 인코포레이티드	방광내 주입을 위한 생물학 제형
RU2585494C2 (ru) *	2014-09-17	2016-05-27	Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России	Рекомбинантный белок rec-mp, содержащий в своем составе последовательности миелопептидов для лечения вторичных иммунодефицитных состояний
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA41374A (fr)	2015-01-20	2017-11-28	Cytomx Therapeutics Inc	Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
HK1248737A1 (zh)	2015-03-26	2018-10-19	哈佛大学校长及研究员协会	工程改造的肉毒杆菌神经毒素
GB201505306D0 (en) *	2015-03-27	2015-05-13	Ipsen Biopharm Ltd	Chimeric polypeptides
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
GB201607901D0 (en) *	2016-05-05	2016-06-22	Ipsen Biopharm Ltd	Chimeric neurotoxins
UA125965C2 (uk) *	2016-07-08	2022-07-20	Чілдренс Медікал Сентр Корпорейшн	Новий ботулінічний нейротоксин та його похідні
EP3504226A1 (en)	2016-08-24	2019-07-03	President and Fellows of Harvard College	Engineered botulinum neurotoxin
WO2018053111A1 (en)	2016-09-15	2018-03-22	University Of Utah Research Foundation	In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
MX2019006444A (es)	2016-12-02	2019-10-30	Bioverativ Therapeutics Inc	Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US10849914B2 (en)	2017-06-12	2020-12-01	University Of Utah Research Foundation	Methods for producing chemoembolic agents for the delivery of anti-cancer agents
EP3664831B1 (en) *	2017-08-11	2023-06-14	University Of Kentucky Research Foundation	Anti-neurodegenerative therapeutic and use
BR112020012641A2 (pt)	2017-12-20	2020-12-01	Allergan, Inc.	polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele
WO2019158745A1 (de) *	2018-02-16	2019-08-22	Bontana Therapies Gmbh	Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
SI3793588T1 (sl)	2018-05-18	2025-07-31	Bioverativ Therapeutics Inc.	Postopki zdravljenja hemofilije A
SG11202105476XA (en)	2018-12-06	2021-06-29	Cytomx Therapeutics Inc	Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
GB202104294D0 (en) *	2021-03-26	2021-05-12	Ipsen Biopharm Ltd	Clostridial neurotoxins comprising an exogenous activation loop
US12077607B2 (en)	2021-09-23	2024-09-03	University Of Utah Research Foundation	Functional and therapeutic effects of PAR4 cleavage by cathepsin G
KR102728382B1 (ko) *	2022-10-12	2024-11-14	주식회사 알케미어	보툴리눔 독소의 경쇄 변이체
KR20250122877A (ko) *	2024-02-07	2025-08-14	주식회사 알케미어	보툴리눔 독소 e형의 경쇄 변이체

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0517805B1 (en)	1990-02-26	2002-07-10	The Board Of Trustees Of The Leland Stanford Junior University	Identification and expression of insect steroid receptor dna sequences
US5364791A (en)	1992-05-14	1994-11-15	Elisabetta Vegeto	Progesterone receptor having C. terminal hormone binding domain truncations
AU685054C (en)	1992-05-14	2003-02-27	Baylor College Of Medicine	Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5464758A (en)	1993-06-14	1995-11-07	Gossen; Manfred	Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en)	1993-06-14	1998-09-29	Basf Aktiengesellschaft	Methods for regulating gene expression
GB9508204D0 (en)	1995-04-21	1995-06-07	Speywood Lab Ltd	A novel agent able to modify peripheral afferent function
GB9617671D0 (en)	1996-08-23	1996-10-02	Microbiological Res Authority	Recombinant toxin fragments
GB9818548D0 (en)	1998-08-25	1998-10-21	Microbiological Res Authority	Treatment of mucas hypersecretion
US6776990B2 (en)	1999-04-08	2004-08-17	Allergan, Inc.	Methods and compositions for the treatment of pancreatitis
US20090018081A1 (en)	1999-08-25	2009-01-15	Allergan, Inc.	Activatable clostridial toxins
US7740868B2 (en)	1999-08-25	2010-06-22	Allergan, Inc.	Activatable clostridial toxins
DE60032367T3 (de)	1999-08-25	2011-03-10	Allergan, Inc., Irvine	Aktivierbare rekombinante neurotoxine
US20030180289A1 (en)	1999-09-23	2003-09-25	Foster Keith Alan	Inhibition of secretion from non-neuronal cells
US7138127B1 (en)	2000-01-19	2006-11-21	Allergan, Inc.	Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en)	2000-01-19	2002-12-31	Allergan, Inc.	Clostridial toxin derivatives and methods for treating pain
US6903187B1 (en)	2000-07-21	2005-06-07	Allergan, Inc.	Leucine-based motif and clostridial neurotoxins
US7491799B2 (en)	2000-07-21	2009-02-17	Allergan, Inc.	Modified botulinum neurotoxins
US20030219462A1 (en)	2000-07-21	2003-11-27	Allergan Sales, Inc	Clostridial neurotoxin compositions and modified clostridial neurotoxins
US7273722B2 (en) *	2000-11-29	2007-09-25	Allergan, Inc.	Neurotoxins with enhanced target specificity
GB0321344D0 (en)	2003-09-11	2003-10-15	Health Prot Agency	Re-targeted toxin conjugates
JP4262072B2 (ja)	2003-12-05	2009-05-13	株式会社日立製作所	自動車用補助機器制御装置
US7514088B2 (en)	2005-03-15	2009-04-07	Allergan, Inc.	Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en)	2004-06-30	2010-10-12	Allergan, Inc.	Multivalent clostridial toxins
US20060024331A1 (en) *	2004-08-02	2006-02-02	Ester Fernandez-Salas	Toxin compounds with enhanced membrane translocation characteristics
DE602005011458D1 (de) *	2004-09-01	2009-01-15	Allergan Inc	Abbaubare clostridientoxine
GB0426397D0 (en)	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
US7659092B2 (en)	2004-12-01	2010-02-09	Syntaxin, Ltd.	Fusion proteins
GB0426394D0 (en)	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
WO2006099590A2 (en)	2005-03-15	2006-09-21	Allergan, Inc.	Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
AU2006339490B2 (en) *	2005-09-19	2011-12-08	Allergan, Inc.	Clostridial toxin activatable clostridial toxins
CA2601537A1 (en)	2006-03-14	2007-09-20	Allergan, Inc.	Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1834962A1 (de) *	2006-03-15	2007-09-19	Biotecon Therapeutics GmbH	PEGyliertes mutiertes Clostridium botulinum Toxin
CA2658260A1 (en)	2006-07-11	2008-01-17	Allergan, Inc.	Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
CA2657521A1 (en)	2006-07-11	2008-01-17	Allergan, Inc.	Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008011157A2 (en) *	2006-07-20	2008-01-24	The General Hospital Corporation	Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US7692222B2 (en)	2006-11-07	2010-04-06	Raytheon Company	Atomic layer deposition in the formation of gate structures for III-V semiconductor
NZ585108A (en) *	2007-10-23	2012-09-28	Allergan Inc	Methods of treating urogenital-neurological disorders using modified clostridial toxins
GB0903006D0 (en) *	2009-02-23	2009-04-08	Syntaxin Ltd	Modified non-cytotoxic proteases
MX369263B (es) *	2010-05-20	2019-11-04	Allergan Inc	Toxinas de clostridium degradables.

2011
- 2011-05-19 MX MX2015015117A patent/MX369263B/es unknown
- 2011-05-19 KR KR1020207028393A patent/KR102321664B1/ko not_active Expired - Fee Related
- 2011-05-19 MX MX2012013381A patent/MX2012013381A/es active IP Right Grant
- 2011-05-19 BR BR112012029666-3A patent/BR112012029666A2/pt not_active Application Discontinuation
- 2011-05-19 WO PCT/US2011/037131 patent/WO2011146704A1/en not_active Ceased
- 2011-05-19 NZ NZ703378A patent/NZ703378A/en not_active IP Right Cessation
- 2011-05-19 SG SG2012085114A patent/SG185663A1/en unknown
- 2011-05-19 EP EP13176290.8A patent/EP2650003B1/en active Active
- 2011-05-19 KR KR1020127033131A patent/KR101942106B1/ko not_active Expired - Fee Related
- 2011-05-19 AU AU2011255525A patent/AU2011255525B2/en not_active Ceased
- 2011-05-19 DK DK16181227.6T patent/DK3106170T3/da active
- 2011-05-19 CN CN201180035613.3A patent/CN103228286B/zh not_active Expired - Fee Related
- 2011-05-19 DK DK11724483.0T patent/DK2571509T3/da active
- 2011-05-19 ES ES11724483.0T patent/ES2596128T3/es active Active
- 2011-05-19 KR KR1020197001617A patent/KR102164166B1/ko not_active Expired - Fee Related
- 2011-05-19 KR KR1020217035259A patent/KR20210132753A/ko not_active Withdrawn
- 2011-05-19 SG SG10201506567UA patent/SG10201506567UA/en unknown
- 2011-05-19 CA CA2799969A patent/CA2799969C/en not_active Expired - Fee Related
- 2011-05-19 UA UAA201214593A patent/UA108646C2/ru unknown
- 2011-05-19 JP JP2013511353A patent/JP6148979B2/ja not_active Expired - Fee Related
- 2011-05-19 EP EP11724483.0A patent/EP2571509B1/en active Active
- 2011-05-19 EP EP16181227.6A patent/EP3106170B1/en active Active
- 2011-05-19 NZ NZ604322A patent/NZ604322A/en not_active IP Right Cessation
- 2011-05-19 ES ES16181227T patent/ES2813650T3/es active Active
- 2011-05-19 RU RU2012154862/10A patent/RU2561465C2/ru active
- 2011-05-19 DK DK13176290.8T patent/DK2650003T3/da active
- 2011-05-19 ES ES13176290.8T patent/ES2600463T3/es active Active
- 2011-05-20 TW TW100117869A patent/TWI516594B/zh not_active IP Right Cessation
- 2011-05-20 AR ARP110101742A patent/AR081407A1/es not_active Application Discontinuation
- 2011-05-20 US US13/112,844 patent/US8512992B2/en not_active Expired - Fee Related
2012
- 2012-11-18 IL IL223100A patent/IL223100B/en active IP Right Grant
- 2012-11-21 ZA ZA2012/08753A patent/ZA201208753B/en unknown
2013
- 2013-03-18 US US13/846,307 patent/US8685692B2/en not_active Expired - Fee Related
- 2013-03-18 US US13/846,338 patent/US8685693B2/en not_active Expired - Fee Related
- 2013-03-18 US US13/846,364 patent/US8841111B2/en active Active
- 2013-08-16 US US13/969,148 patent/US8697413B2/en active Active
- 2013-08-16 US US13/969,174 patent/US8697414B2/en active Active
- 2013-11-21 US US14/086,840 patent/US9279116B2/en active Active
- 2013-11-22 US US14/088,022 patent/US9297003B2/en active Active
- 2013-11-22 US US14/087,952 patent/US9284545B2/en active Active
2015
- 2015-08-07 JP JP2015157372A patent/JP6220830B2/ja not_active Expired - Fee Related
2016
- 2016-03-28 US US15/082,635 patent/US9850476B2/en not_active Expired - Fee Related
2017
- 2017-07-06 JP JP2017133024A patent/JP6467000B2/ja not_active Expired - Fee Related
- 2017-12-18 US US15/845,572 patent/US10501731B2/en active Active
2019
- 2019-01-10 JP JP2019002677A patent/JP6644177B2/ja not_active Expired - Fee Related
- 2019-12-09 US US16/707,187 patent/US20200190496A1/en not_active Abandoned
2022
- 2022-09-23 US US17/934,914 patent/US20240018500A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK3106170T3 (da)	2020-07-13
RU2561465C2 (ru)	2015-08-27
US8512992B2 (en)	2013-08-20
EP3106170B1 (en)	2020-04-08
US20110287517A1 (en)	2011-11-24
KR20130054967A (ko)	2013-05-27
TWI516594B (zh)	2016-01-11
AR081407A1 (es)	2012-08-29
BR112012029666A2 (pt)	2020-10-06
JP6148979B2 (ja)	2017-06-14
UA108646C2 (xx)	2015-05-25
NZ604322A (en)	2015-01-30
EP3106170A1 (en)	2016-12-21
US9284545B2 (en)	2016-03-15
AU2011255525B2 (en)	2015-09-10
US8697414B2 (en)	2014-04-15
WO2011146704A1 (en)	2011-11-24
EP2571509A1 (en)	2013-03-27
US8685692B2 (en)	2014-04-01
US20140220627A1 (en)	2014-08-07
JP6220830B2 (ja)	2017-10-25
US20140227740A1 (en)	2014-08-14
US20180119126A1 (en)	2018-05-03
US20130196414A1 (en)	2013-08-01
US20240018500A1 (en)	2024-01-18
KR102164166B1 (ko)	2020-10-13
TW201142026A (en)	2011-12-01
ES2596128T3 (es)	2017-01-05
US20160201046A1 (en)	2016-07-14
US8697413B2 (en)	2014-04-15
ES2600463T3 (es)	2017-02-09
CA2799969C (en)	2019-06-25
US20140127783A1 (en)	2014-05-08
US9297003B2 (en)	2016-03-29
MX369263B (es)	2019-11-04
CA2799969A1 (en)	2011-11-24
US9279116B2 (en)	2016-03-08
MX2012013381A (es)	2013-02-21
SG185663A1 (en)	2012-12-28
JP6467000B2 (ja)	2019-02-06
KR102321664B1 (ko)	2021-11-04
IL223100A0 (en)	2013-02-03
US8685693B2 (en)	2014-04-01
DK2571509T3 (da)	2016-10-24
KR20190010720A (ko)	2019-01-30
EP2650003A1 (en)	2013-10-16
KR20200118234A (ko)	2020-10-14
US10501731B2 (en)	2019-12-10
IL223100B (en)	2018-02-28
SG10201506567UA (en)	2015-10-29
EP2650003B1 (en)	2016-07-27
JP6644177B2 (ja)	2020-02-12
KR101942106B1 (ko)	2019-01-25
AU2011255525A1 (en)	2012-12-20
CN103228286A (zh)	2013-07-31
US20130330806A1 (en)	2013-12-12
US20130273633A1 (en)	2013-10-17
JP2015193669A (ja)	2015-11-05
JP2019088296A (ja)	2019-06-13
US20130330807A1 (en)	2013-12-12
US20130288334A1 (en)	2013-10-31
US20200190496A1 (en)	2020-06-18
US9850476B2 (en)	2017-12-26
EP2571509B1 (en)	2016-07-06
US8841111B2 (en)	2014-09-23
KR20210132753A (ko)	2021-11-04
CN103228286B (zh)	2018-01-02
JP2013529213A (ja)	2013-07-18
JP2018012696A (ja)	2018-01-25
NZ703378A (en)	2016-10-28
ZA201208753B (en)	2013-09-25
HK1180592A1 (zh)	2013-10-25
ES2813650T3 (es)	2021-03-24
RU2012154862A (ru)	2014-06-27

Publication	Publication Date	Title
DK3106170T3 (da)	2020-07-13	Nedbrydelige clostridiumtoksiner
BR112013015783A2 (pt)	2018-05-29	autoinjetor.
DK2536452T3 (da)	2019-01-02	Autoinjektor
DK2585140T3 (da)	2019-10-14	Autoinjektor
DK2585137T3 (da)	2019-11-04	Autoinjektor
BR112013008072A2 (pt)	2016-06-14	autoinjetor
BR112013008401A2 (pt)	2016-06-21	autoinjetor
DK2654833T3 (da)	2019-05-20	Autoinjektor
BR112012028556A2 (pt)	2014-04-01	Indóis
DE102011100241A8 (de)	2012-03-01	Nitridhalbleiterbauteil
DK2654842T3 (da)	2020-01-06	Autoinjektor
DE10170954T8 (de)	2013-04-25	Mikrowellendruckgarer
BR112013007610A2 (pt)	2016-07-26	benzoxazinonas herbecidas
DE112011104226A5 (de)	2013-09-26	Käfigmutter
DE102011117046A8 (de)	2012-12-27	Doppelkupplungswindungsgetriebe
DE112011101226A5 (de)	2013-01-24	Linearwegmesssystem
DE112011102080A5 (de)	2013-04-11	Kupplungszentralausrücker
DE102010038420A8 (de)	2013-01-10	Reinigungungsvorrichtung
DE112011101333A5 (de)	2013-01-24	Parkouraufbau
DE102011002623A8 (de)	2012-02-02	Ventilsteuerzeitversteller
DE112011102711A5 (de)	2013-05-29	Hydrostataktor
DE102010035554B8 (de)	2014-12-24	Fußtüröffner
DE102010019119B8 (de)	2013-01-31	Cuttermesser
BR112013015785A2 (pt)	2018-11-06	autoinjetor
DE112010005518A5 (de)	2013-04-25	Dichtungsmanchette